SCHEMBL14403284

SCHEMBL14403284

COc1cc(C)ccc1OP(=O)(O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.61
INPPL1 O15357 5/20 0.52
INPP5A Q14642 3/20 0.52
AKT1 P31749 1/20 0.48
INPP5B P32019 1/20 0.48
ALDH1A1 P00352 3/20 0.46
CYP3A4 P08684 2/20 0.46
L3MBTL1 Q9Y468 5/20 0.44
MAPT P10636 3/20 0.44
CYP2C9 P11712 2/20 0.44
HPGD P15428 2/20 0.44
CYP2C19 P33261 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
POLB P06746 1/20 0.44
ALOX12 P18054 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL8941755 0.91 ACHE (0.50) ACHEINPPL1INPP5AALDH1A1CYP3A4
SCHEMBL7591862 0.81 INPPL1 (0.48) ACHEINPPL1INPP5AAKT1INPP5B
SCHEMBL8620844 0.81 INPPL1 (0.52) INPPL1INPP5AAKT1INPP5BCYP2C9
SCHEMBL109597 0.81 INPPL1 (0.52) INPPL1INPP5AAKT1INPP5BHPGD
SCHEMBL20107983 0.80 INPPL1 (0.50) INPPL1INPP5AAKT1INPP5BALDH1A1
SCHEMBL27559347 0.79 INPPL1 (0.50) INPPL1INPP5AAKT1INPP5BHPGD
SCHEMBL28656347 0.79 INPPL1 (0.50) INPPL1INPP5AAKT1INPP5BTDP1
SCHEMBL14274128 0.78 INPPL1 (0.52) INPPL1INPP5AAKT1INPP5BALDH1A1
SCHEMBL31406716 0.78 INPPL1 (0.48) INPPL1INPP5AAKT1INPP5BALDH1A1
SCHEMBL11360950 0.78 INPPL1 (0.48) INPPL1INPP5AAKT1INPP5BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151024-A1 STING AGONISTIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-18 US disclosed
EP-4134134-A1 STING AGONISTIC COMPOUND ONO Pharmaceutical Co., Ltd. (JP) 2023-02-15 EP disclosed
EP-4134098-A1 METHOD OF CANCER THERAPY ONO Pharmaceutical Co., Ltd. (JP) 2023-02-15 EP disclosed
US-20070248692-A1 COMBINATION THERAPY USING PENTAFLUOROBENZENESULFONAMIDES AND ANTINEOPLASTIC AGENTS AMGEN INC. (US) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070248692-A1 COMBINATION THERAPY USING PENTAFLUOROBENZENESULFONAMIDES AND ANTINEOPLASTIC AGENTS ETV6, FANCF, FANCI ACHE 4594/4885INPPL1 2472/4885INPP5A 3362/4885
US-20230151024-A1 STING AGONISTIC COMPOUND STING1, CGAS, TLR1 ACHE 819/4885INPPL1 284/4885INPP5A 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.